{"id":"NCT02791230","sponsor":"Pfizer","briefTitle":"Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy","officialTitle":"A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-13","primaryCompletion":"2023-10-26","completion":"2023-11-02","firstPosted":"2016-06-06","resultsPosted":"2025-02-03","lastUpdate":"2025-02-03"},"enrollment":1733,"design":{"allocation":"NA","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Transthyretin (TTR) Amyloid Cardiomyopathy"],"interventions":[{"type":"DRUG","name":"Tafamidis","otherNames":[]}],"arms":[{"label":"Tafamidis","type":"EXPERIMENTAL"}],"summary":"Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy","primaryOutcome":{"measure":"Time to All-Cause Mortality: Cohort A","timeFrame":"From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]","effectByArm":[{"arm":"Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study)","deltaMin":58.7,"sd":null},{"arm":"Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study)","deltaMin":35.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":80,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Czechia","France","Germany","Hong Kong","Italy","Japan","Netherlands","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["40488446","38932583","37943223","37434378","36715498","34923848","33070419","32524297"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B3461045"]},"adverseEventsSummary":{"seriousAny":{"events":132,"n":170},"commonTop":["Fall","Atrial fibrillation","Cardiac failure","Dyspnoea","Constipation"]}}